Gainers

• INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release, Q2 earnings came out today.
• OSR Health (NASDAQ:OSRH) stock rose 83.98% to $0.58. The company's market cap stands at $11.0 million.
• Acurx Pharmaceuticals (NASDAQ:ACXP) shares rose 20.07% to $1.68. The company's market cap stands at $5.9 million. As per the press release, Q2 earnings came out yesterday.
• Axe Compute (NASDAQ:AGPU) stock moved upwards by 18.63% to $9.81. The company's market cap stands at $94.1 million. The company's, Q2 earnings came out yesterday.
• Nanobiotix (NASDAQ:NBTX) stock increased by 17.93% to $45.18. The company's market cap stands at $1.9 billion.
• argenx (NASDAQ:ARGX) shares moved upwards by 15.99% to $987.46. The company's market cap stands at $53.2 billion.

Losers

• EyePoint (NASDAQ:EYPT) stock declined by 69.0% to $4.58 during Monday's regular session. The market value of their outstanding shares is at $1.2 billion.
• NexGel (NASDAQ:NXGL) shares fell 28.29% to $0.41. The market value of their outstanding shares is at $5.2 million. The company's, Q2 earnings came out today.
• Citius Pharmaceuticals (NASDAQ:CTXR) shares declined by 25.4% to $0.56. The market value of their outstanding shares is at $20.7 million. As per the press release, Q3 earnings came out yesterday.
• BioXcel Therapeutics (NASDAQ:BTAI) stock decreased by 24.98% to $0.89. The market value of their outstanding shares is at $36.7 million. The company's, Q2 earnings came out 2 days ago.
• OneMedNet (NASDAQ:ONMD) stock fell 21.38% to $0.61. The market value of their outstanding shares is at $44.4 million.
• Akanda (NASDAQ:AKAN) stock fell 20.78% to $5.11. The market value of their outstanding shares is at $3.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.